Bone marrow changes favor mutant blood cells in mice
In mouse experiments, removing senescent cells—cells that have stopped dividing—reduced mutant blood cell expansion and delayed progression to blood cancer.
Limit: Only four biological replicates per group in the marrow cell analysis
Stake: An author holds shares in Imago BioSciences. An author holds patents with Fate Therapeutics.
Edited by Boris Djordjevic · AgingResearch.News
In mice modeling clonal hematopoiesis, the expansion of blood cells descended from a mutated stem cell, researchers investigated changes in bone marrow support cells. They measured gene activity in individual marrow cells 12 weeks after transplantation, with four biological replicates per group.
Mutant blood-forming cells induced senescence, a state in which cells stop dividing, in nearby support cells. They did this through soluble signals, without cell-to-cell contact. Genetic or drug-based depletion of senescent cells outside the blood-forming system reduced the burden of mutant blood cells and delayed progression to blood cancer. The researchers also observed elevated marrow support-cell senescence in humans with clonal hematopoiesis.
Why it matters
The work addresses how cellular senescence might shape a precancerous process. The authors propose disrupting communication between mutant blood cells and their surroundings as a cancer prevention strategy.
Caveats
The depletion results came from experiments in mouse models. Whether removing senescent cells prevents blood cancer in people was not tested.
- Senolytics
- DNMT3A
- Cellular senescence
- Myeloid neoplasia
- Clonal hematopoiesis of indeterminate potential
- Mice
The paper
Stromal cell senescence augments haematopoietic cell fitness in clonal haematopoiesis
Jackson Laboratory
Nature Cell Biology, Aug 6, 2026, Open access
